Urea Cream Treatment Sorafenib-Associated HSFR in HCC
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Although sorafenib is effective and safe in patients with advanced hepatocellular carcinoma
(HCC), it increases dermatologic toxicities, including hand-foot skin reaction (HFSR), which
may have a negative impact on patient quality of life (QoL). Urea-based creams may have a
prophylactic effect on sorafenib-induced HFSR in HCC patients.